Piper Sandler Maintains Overweight on Avadel Pharmaceuticals, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and increased the price target from $18 to $23.
March 05, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Avadel Pharmaceuticals and raised the price target from $18 to $23.
The increase in price target by a reputable analyst firm like Piper Sandler typically signals a strong bullish outlook on the stock, suggesting a potential upside. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100